Genmab to submit cancer candidate epcoritamab to the FDA before year-end

During the second half of 2022, Genmab and partner Abbvie will submit an application for marketing authorization from the FDA concerning their candidate epcoritamab. The target indication is relapsed/refractory large B-cell lymphoma (LBCL).
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Analyst: Genmab cancer data is promising compared to rival
For subscribers
Genmab presents full data set for cancer drug
For subscribers
Genmab to buy back 370,000 shares
For subscribers